Your browser doesn't support javascript.
loading
Smart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden: A Cost-Effectiveness Analysis.
Jendle, Johan; Ericsson, Åsa; Gundgaard, Jens; Møller, Jonas Bech; Valentine, William J; Hunt, Barnaby.
Affiliation
  • Jendle J; Institute of Medical Sciences, Örebro University, Örebro, Sweden. johan.jendle@oru.se.
  • Ericsson Å; Novo Nordisk Scandinavia AB, Malmö, Sweden.
  • Gundgaard J; Novo Nordisk A/S, Søborg, Denmark.
  • Møller JB; Novo Nordisk A/S, Søborg, Denmark.
  • Valentine WJ; Ossian Health Economics and Communications, Basel, Switzerland.
  • Hunt B; Ossian Health Economics and Communications, Basel, Switzerland.
Diabetes Ther ; 12(1): 373-388, 2021 Jan.
Article in En | MEDLINE | ID: mdl-33306169
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Health_economic_evaluation / Health_technology_assessment / Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Language: En Journal: Diabetes Ther Year: 2021 Document type: Article Affiliation country: Sweden Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Health_economic_evaluation / Health_technology_assessment / Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Language: En Journal: Diabetes Ther Year: 2021 Document type: Article Affiliation country: Sweden Country of publication: United States